We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
EKF Diagnostics Novel Diabetic Biomarker Test Successfully Externally Verified
Product News

EKF Diagnostics Novel Diabetic Biomarker Test Successfully Externally Verified

EKF Diagnostics Novel Diabetic Biomarker Test Successfully Externally Verified
Product News

EKF Diagnostics Novel Diabetic Biomarker Test Successfully Externally Verified


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "EKF Diagnostics Novel Diabetic Biomarker Test Successfully Externally Verified"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

EKF Diagnostics has announced that its newly introduced Glycated Serum Protein (GSP) LiquiColor® diabetic biomarker test has been verified for use on the Siemens Vista chemistry analyzer. In a scientific poster published by scientists at the Memorial Healthcare System, Hollywood, USA [1], it was demonstrated that EKF’s GSP assay enhances the versatility of the Vista system for the specialized glycemic monitoring of diabetics with hemoglobinopathies, or conditions that affect red blood cell (RBC) lifespan.
 
Daily blood glucose and HbA1c are used as short and long term (3-4 month) measures of glycemic control respectively. However, HbA1c values may be adversely affected by patients with hemoglobin variants or conditions that affect RBC lifespan such as anemia and dialysis to name a few, while GSP as a 2-3 week indicator of blood glucose, is unaffected. Traditional NBT assays for fructosamine (or GSP), used as an alternative test for diabetes patients with hemoglobinopathies and pregnant women, suffer from a variety of interferences.


Due to these analytical issues, the Memorial Healthcare System scientists required a reliable alternative that could be adapted to their existing analyzer. Therefore, the EKF Diagnostics GSP assay was evaluated and validated using an open channel user defined method. The scientific poster authors concluded that EKF’s GSP assay provides laboratories with a simple, sensitive and fast alternative glycemic monitoring test without the endogenous substance interference that are typically observed in NBT based colorimetric assays.
 
“We are pleased with the recognition by the Memorial Health System of the value of our GSP diabetic biomarker test which is based on a double enzymatic degradation method. This provides superior specificity, accuracy and reliability compared to the older non-enzymatic fructosamine NBT method,” said Al Blanco, Business Unit Director – Central Lab at EKF Diagnostics.
 
He added, “As a 2-3 week indicator of average blood glucose which is unaffected by RBC half-life, GSP closes the information gap between daily blood glucose and HbA1c testing. This means that GSP serves as an accurate intermediate marker of glycemia in instances where HbA1c may be of limited value, such as pregnancy, reduced RBC lifespan and hemodialysis.” The Memorial Health System scientific poster presented at the American Association for Clinical Chemistry (AACC) Annual Scientific Meeting 2016 is available to view at: http://www.ekfdiagnostics.com/glycated-serum-protein.html.

Advertisement